<DOC>
	<DOCNO>NCT02103283</DOCNO>
	<brief_summary>A Phase 1 Study evaluate Safety teprotumumab Patients Diabetic Macular Edema .</brief_summary>
	<brief_title>A Phase 1 , Open-Label Study Teprotumumab Patients With Diabetic Macular Edema ( DME )</brief_title>
	<detailed_description>A Phase 1 , Open-Label Safety Pharmacodynamic Study RV 001 , Insulin-Like Growth Factor-1 Receptor ( IGF-1 ) Antagonist , Given By IV Infusion Patients Diabetic Macular Edema ( DME ) .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>Diagnosis diabetes mellitus Hemoglobin A1c &lt; 8.5 % IGF 1 serum &gt; 106 ng/mL Women childbearing potential must negative pregnancy test willing able use two different method contraception , one must oral contraceptive depot formulation . Males must surgically sterile agree use barrier contraception Clinically significant DME le 12 month duration Nonproliferative diabetic retinopathy moderate severity Best correct electronic ETDRS letter score &lt; 78 &gt; 24 Unstableuncontrolled diabetes demonstrate change diabetes medication great 15 % previous 60 day . Significant renal disease , myocardial infarction , stroke , transient ischemic attack , acute congestive heart failure Blood pressure &gt; 180/110 Antivascular endothelial growth factor ( VEGF ) treatment within two month prior enrollment History pan retinal photocoagulation within four month prior enrollment History ocular surgery within four month prior enrollment History systemic treatment corticosteroid within 3 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>